The “ABC” of Virus-Specific T Cell Immunity in Solid Organ Transplantation

American Journal of Transplantation

Volumn 16, Issue 6, 2016, Pages 1697-1706

  Sester, M ^a   Leboeuf, C ^b   Schmidt, T ^a   Hirsch, H H ^b,c  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE; ADOPTIVE TRANSFER; BK VIRUS; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; HUMAN; IMMUNOASSAY; MICROBIAL DIVERSITY; NONHUMAN; ORGAN TRANSPLANTATION; PRELIMINARY COMMUNICATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS; VIRUS CHARACTERIZATION; VIRUS IMMUNITY;

EID: 84978880072     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13684     Document Type: Review

References (73)

1. Hirsch HH. Virus infections post transplant: Risk and immunity. Transpl Infect Dis 2005; 7(3–4): 97–98.
2. Klenerman P, Hill A. T cells and viral persistence: Lessons from diverse infections. Nat Immunol 2005; 6(9): 873–879.
3. Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24(2): 339–371.
4. Suwelack B, Malyar V, Koch M, Sester M, Sommerer C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) 2012; 26(3): 201–211.
5. Sester M, Gärtner BC, Sester U. Monitoring of CMV specific T-cell levels after organ transplantation. J Lab Med 2008; 32(3): 121–130.
6. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96(4): 333–360.
7. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004; 173(3): 1834–1841.
8. Dirks J, Tas H, Schmidt T, et al. PD-1 analysis on CD28(-) CD27(-) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant 2013; 13(12): 3132–3141.
9. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9(5): 1214–1222.
10. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 2013; 56(6): 817–824.
11. Leyking S, Budich K, van Bentum K, et al. Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients. J Transl Med 2015; 13(1): 51.
12. Kirsch S, Thijssen S, Alarcon Salvador S, et al. T-cell numbers and antigen-specific T-cell function follow different circadian rhythms. J Clin Immunol 2012; 32(6): 1381–1389.
13. Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation 2009; 88(10): 1161–1168.
14. Florescu DF, Hoffman JA; AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 206–211.
15. Hirsch HH, Pergam SA. Human adenovirus, polyomavirus, and parvovirus infections in patients undergoing hematopoietic stem-cell transplantation. In: Forman SJ, Antin H, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. 5th ed. Chichester, UK: John Wiley & Sons Ltd, 2015; p. 1090–1104.
16. Hoffman JA. Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant 2009; 14(6): 625–633.
17. Sandkovsky U, Vargas L, Florescu DF. Adenovirus: Current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep 2014; 16(8): 416.
18. Sester M, Sester U, Alarcon Salvador S, et al. Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 2002; 185(10): 1379–1387.
19. Geyeregger R, Freimuller C, Stevanovic S, et al. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS ONE 2013; 8(4): e59592.
20. Imahashi N, Nishida T, Ito Y, et al. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy. Mol Immunol 2013; 56(4): 399–405.
21. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6(242): 242–283.
22. Florescu DF, Islam MK, Mercer DF, et al. Adenovirus infections in pediatric small bowel transplant recipients. Transplantation 2010; 90(2): 198–204.
23. Hirsch HH, Babel N, Comoli P, et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clin Microbiol Infect 2014; 20(Suppl 7): 74–88.
24. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347(7): 488–496.
25. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 179–188.
26. Hirsch HH, Yakhontova K, Lu M, Manzetti J. BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant 2016; 16: 821–832.
27. Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: A prospective, randomized, multicenter study. Am J Transplant 2013; 13(1): 136–145.
28. Tedesco Silva H Jr., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10(6): 1401–1413.
29. Funk GA, Gosert R, Comoli P, Ginevri F, Hirsch HH. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant 2008; 8: 2368–2377.
30. Comoli P, Azzi A, Maccario R, et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004; 78(8): 1229–1232.
31. Binggeli S, Egli A, Schaub S, et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7(5): 1131–1139.
32. Ginevri F, Basso S, Hirsch HH, et al. Reconstitution of BKV-specific immunity through immunosuppression reduction prevents BKV nephropathy in pediatric kidney recipients monitored prospectively. Transpl Int 2007; 20: 80–80.
33. Binggeli S, Egli A, Dickenmann M, Binet I, Steiger J, Hirsch HH. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant 2006; 6(9): 2218–2219; author reply 2220.
34. Leuenberger D, Andresen PA, Gosert R, et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol 2007; 14(8): 959–968.
35. Schachtner T, Muller K, Stein M, et al. BK virus-specific immunity kinetics: A predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 2011; 11(11): 2443–2452.
36. Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation 2008; 85(2): 185–192.
37. Mueller K, Schachtner T, Sattler A, et al. BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 2011; 91(1): 100–107.
38. Schachtner T, Stein M, Babel N, Reinke P. The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication. Am J Transplant 2015; 15(8): 2159–2169.
39. Trydzenskaya H, Sattler A, Muller K, et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation 2011; 92(11): 1269–1277.
40. Weist BJ, Schmueck M, Fuehrer H, Sattler A, Reinke P, Babel N. The role of CD4(+) T cells in BKV-specific T cell immunity. Med Microbiol Immunol 2014; 203(6): 395–408.
41. Schmidt T, Adam C, Hirsch HH, et al. BK polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication. Am J Transplant 2014; 14(6): 1334–1345.
42. Bodaghi S, Comoli P, Bosch R, et al. Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in young kidney transplant patients. J Clin Microbiol 2009; 47(8): 2577–2585.
43. Li J, Melenhorst J, Hensel N, et al. T-cell responses to peptide fragments of the BK virus T antigen: Implications for cross-reactivity of immune response to JC virus. J Gen Virol 2006; 87(Pt 10): 2951–2960.
44. Krymskaya L, Sharma MC, Martinez J, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005; 79(17): 11170–11178.
45. Cioni M, Leboeuf C, Comoli P, Ginevri F, Hirsch HH. Characterization of Immunodominant BK Polyomavirus 9mer-Epitope T-cell Responses. Am J Transplant 2016; 16(1): in press.
46. Lilleri D, Zelini P, Fornara C, Comolli G, Revello MG, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clin Immunol 2009; 131(3): 395–403.
47. Sester M, Gärtner BC, Sester U, Girndt M, Mueller-Lantzsch N, Köhler H. Is the CMV serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003; 76(8): 1229–1231.
48. Schmidt T, Ritter M, Dirks J, Gärtner BC, Sester U, Sester M. Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: A proof of principle. J Clin Virol 2012; 54(3): 272–275.
49. Ritter M, Schmidt T, Dirks J, et al. Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 2013; 43(4): 1099–1108.
50. Abate D, Saldan A, Mengoli C, et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol 2013; 51(8): 2501–2507.
51. Cantisan S, Lara R, Montejo M, et al. Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013; 13(3): 738–745.
52. Lucia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis 2014; 59(11): 1537–1545.
53. Sester M, Sester U, Gärtner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71(9): 1287–1294.
54. Weseslindtner L, Kerschner H, Steinacher D, et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012; 12(8): 2172–2180.
55. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6(1): 29.
56. Dirks J, Egli A, Sester U, Sester M, Hirsch HH.Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells. Transpl Infect Dis 2013; 15: 79–89.
57. Sester U, Presser D, Dirks J, Gärtner BC, Köhler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8: 1486–1497.
58. La Rosa C, Krishnan A, Longmate J, et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008; 197(1): 25–33.
59. Nebbia G, Mattes FM, Smith C, et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008; 8(12): 2590–2599.
60. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8(5): 990–999.
61. Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 107–120.
62. Wilsdorf N, Eiz-Vesper B, Henke-Gendo C, et al. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease. Transplantation 2013; 95(1): 247–255.
63. Ritta M, Costa C, Sinesi F, et al. Evaluation of Epstein-Barr virus-specific immunologic response in solid organ transplant recipients with an enzyme-linked ImmunoSpot assay. Transplant Proc 2013; 45(7): 2754–2757.
64. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007; 17(3): 203–210.
65. Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011; 32(4): 471–493.
66. Coughlan L, Lambe T. Measuring cellular immunity to influenza: Methods of detection, applications and challenges. Vaccines (Basel) 2015; 3(2): 293–319.
67. Schmidt T, Dirks J, Enders M, et al. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur J Immunol 2012; 42(7): 1755–1766.
68. Pergam SA, Limaye AP. Varicella zoster virus in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 138–146.
69. Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: Safe and immunogenic. Am J Transplant 2012; 12(11): 2974–2985.
70. Schub D, Janssen E, Leyking S, et al. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection. J Infect Dis 2015; 211(4): 600–612.
71. Holmes-Liew CL, Holmes M, Beagley L, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunology 2015; 4(3): e35.
72. Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009; 9(7): 1679–1684.
73. Ahlenstiel-Grunow T, Koch A, Grosshennig A, et al. A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): Study protocol for a randomized controlled trial. Trials 2014; 15: 324.